Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib

Molecular Cancer Therapeutics

Volumn 6, Issue 1, 2007, Pages 61-69

  An, Jiabin ^a   Rettig, Matthew B ^a,b  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; BORTEZOMIB; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; DRUG TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; KIDNEY CARCINOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CARCINOMA, RENAL CELL; CELL CYCLE; CELL DEATH; CELL SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; INHIBITORY CONCENTRATION 50; KIDNEY NEOPLASMS; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33846805694     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0255     Document Type: Article

References (54)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Waters WB, Richie JP. Aggressive surgical approach to renal cell carcinoma: review of 130 cases. J Urol 1979;122:306-9.
3. Glaspy JA. Therapeutic options in the management of renal cell carcinoma. Semin Oncol 2002;29:41-6.
4. Godley P, Kim SW. Renal cell carcinoma. Curr Opin Oncol 2002;14: 280-5.
5. Nathan PD, Eisen TG. The biological treatment of renal-cell carcinoma and melanoma. Lancet Oncol 2002;3:89-96.
6. Atkins MB, George D, Jonasch E. Medical management of renal cell carcinoma. In: UpToDate. Rose BD, editor. UpToDate. Wellesley, MA: 2006.
7. Patel PH, Chaganti RS, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 2006;94:614-9.
8. Davis NB, Taber DA, Ansari RH, et al. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol 2004;22:115-9.
9. Kondagunta GV, Drucker B, Schwartz L, et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 2004;22:3720-5.
10. Mitchell BS. The proteasome - an emerging therapeutic target in cancer. N Engl J Med 2003;348:2597-8.
11. Baldwin AS, Jr. Series introduction: the transcription factor NF-κB and human disease. J Clin Invest 2001; 107:3-6.
12. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS, Jr. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999;19:5785-99.
13. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Invest 2001;107:135-42.
14. Grumont RJ, Rourke IJ, Gerondakis S. Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes Dev 1999; 13:400-11.
15. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 2001;107:241-6.
16. Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10.
17. Rayet B, Gelinas C. Aberrant rel/NF-κB genes and activity in human cancer. Oncogene 1999; 18:6938-47.
18. Oya M, Ohtsubo M, Takayanagi A, et al. Constitutive activation of nuclear factor-κB prevents TRAIL-induced apoptosis in renal cancer cells. Oncogene 2001;20:3888-96.
19. Qi H, Ohh M. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-κB-dependent antiapoptotic pathway. Cancer Res 2003; 63:7076-80.
20. Oya M, Takayanagi A, Horiguchi A, et al. Increased nuclear factor-κB activation is related to the tumor development of renal cell carcinoma. Carcinogenesis 2003;24:377-84.
21. An J, Sun Y, Fisher M, Rettig MB. Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-κB dependent. Mol Cancer Ther 2004;3:727-36.
22. Kondo K, Kaelin WG, Jr. The von Hippel-Lindau tumor suppressor gene. Exp Cell Res 2001;264:117-25.
23. Herman JG, Latif F, Wang Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 1994;91:9700-4.
24. An J, Fisher M, Rettig MB. VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-κB-dependent mechanism. Oncogene 2005;24:1563-70.
25. An J, Rettig MB. Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor κB (NF-κB) activity. Mol Cell Biol 2005;25: 7546-56.
26. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
27. An J, Fisher M, Rettig MB. VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-κB-dependent mechanism. Oncogene 2004;24:1563-70.
28. Fry DW, Kraker AJ, McMichael A, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994;265: 1093-5.
29. Songyang Z, Baltimore D, Cantley LC, Kaplan DR, Franke TF. Interleukin 3-dependent survival by the Akt protein kinase. Proc Natl Acad Sci U S A 1997;94:11345-50.
30. Shen Y, Shenk T. Relief of p53-mediated transcriptional repression by the adenovirus E1B 19-kDa protein or the cellular Bcl-2 protein. Proc Natl Acad Sci U S A 1994;91:8940-4.
31. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
32. Chen F, Kishida T, Duh FM, et al. Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. Cancer Res 1995;55:4804-7.
33. Gnarra JR, Zhou S, Merrill MJ, et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A 1996;93:10589-94.
34. Turner KJ, Moore JW, Jones A, et al. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 2002;62:2957-61.
35. Sowter HM, Raval RR, Moore JW, Ratcliffe PJ, Harris AL. Predominant role of hypoxia-inducible transcription factor (Hif)-1α versus Hif-2α in regulation of the transcriptional response to hypoxia. Cancer Res 2003; 63:6130-4.
36. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in hypoxic gene regulation. Mol Cell Biol 2003;23:9361-74.
37. Adams J. Potential for proteasome inhibition in the treatment of cancer. Drug Discov Today 2003;8:307-15.
38. 2/M phase contributes to survival during mitotic cell cycle arrest. Biochem J 2006;399:335-42.
39. 2/M phase increased in human nasopharyngeal carcinoma cell line by EBV-LMP1 through activation of NF-κB and AP-1. Cell Res 2003;13:187-94.
40. 2/M cell cycle arrest. BMC Cancer 2006;6:107.
41. Gatto S, Scappini B, Pham L, et al. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica 2003;88: 853-63.
42. Pozarowski P, Halicka DH, Darzynkiewicz Z. Cell cycle effects and caspase-dependent and independent death of HL-60 and Jurkat cells treated with the inhibitor of NF-κB parthenolide. Cell Cycle 2003; 2: 377-83.
43. Kucharczak J, Simmons MJ, Fan Y, Gelinas C. To be, or not to be: NF-κB is the answer-role of Rel/NF-κB in the regulation of apoptosis. Oncogene 2003; 22:8961-82.
44. Karin M, Yamamoto Y, Wang QM. The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov 2004;3:17-26.
45. Dawson NA, Guo C, Zak R, et al. A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin Cancer Res 2004;10:7812-9.
46. Drucker B, Bacik J, Ginsberg M, et al. Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Invest New Drugs 2003;21:341-5.
47. Motzer RJ, Amato R, Todd M, et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 2003;21:99-101.
48. Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004;22:3003-15.
49. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61: 3071-6.
50. An J, Sun Y, Fisher M, Rettig MB. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia 2004;18: 1699-704.
51. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-κB activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003; 171: 88-95.
52. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348: 2609-17.
53. O'Connor OA. The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas. Curr Treat Options Oncol 2004;5:269-81.
54. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-7.